Synthesis: What is TNBC?

Evidence grades (GRADE-adapted): A high — multiple well-conducted RCTs or systematic reviews converge. B moderate — single pivotal RCT or consistent observational evidence. C limited — single observational study, mechanistic, or expert consensus. D preclinical / hypothesis-generating.

Definition

Triple-negative breast cancer is defined by the absence of all three standard immunohistochemical (IHC) targets:

• Estrogen receptor (ER): < 1% of cancer-cell nuclei stain positive on IHC^[1]A
• Progesterone receptor (PR): < 1% of nuclei positive^[1]A
• HER2: IHC score 0 or 1+, or IHC 2+ with negative ERBB2 in-situ hybridization^[2]A

The HER2-low category — IHC 1+ or 2+ without amplification — sits inside the historical TNBC definition but is now an actionable category in the metastatic setting (see Standard of care below). Approximately half of historically TNBC tumors are HER2-low under modern reading of the ASCO/CAP guidelines^[3]B.

Epidemiology

TNBC accounts for approximately 10–15% of newly diagnosed breast cancers in unselected Western populations^[4]A. Prevalence varies substantially by population:

• Higher in younger women (under 40)^[5]A
• Higher in women of African ancestry; the Carolina Breast Cancer Study reported roughly two-fold higher prevalence in young African American women compared with non-Hispanic white women^[5], and the international Henry Ford cohort confirmed the ancestry signal independent of country of residence^[6]B
• Strongly enriched in germline BRCA1 carriers; approximately 70% of BRCA1-associated breast cancers display a triple-negative phenotype^[7]A
• Population-level distribution differs across geographies in ways that are not fully explained by ancestry alone (parity, age at first pregnancy, breastfeeding duration, and socioeconomic factors all contribute)^[4]C

Disparities in TNBC outcomes are substantial and are partly but not fully attributable to access and stage at diagnosis^[5]B. A focused disparities synthesis is forthcoming under domain A.

Molecular heterogeneity

"TNBC" is a clinical-diagnostic category defined by absence rather than by a unifying positive feature. At the transcriptomic level it encompasses several biologically distinct subtypes:

Intrinsic-subtype framework

The intrinsic subtypes (luminal A, luminal B, HER2-enriched, basal-like, normal-like) were defined by Perou and colleagues in 2000 and refined into the PAM50 classifier subsequently^[8]A. Approximately 80% of TNBC tumors are basal-like by PAM50, but the overlap is not perfect — a meaningful minority of TNBC tumors are HER2-enriched, luminal, or normal-like by intrinsic-subtype classification^[7].

TNBC-specific subtypes

Two principal TNBC-specific frameworks have been proposed:

• Lehmann / Pietenpol 2011: six subtypes (BL1, BL2, IM, M, MSL, LAR) derived from gene-expression analysis of 587 TNBC samples^[9]A. Subsequent refinement to four subtypes (BL1, BL2, M, LAR) after correcting for tumor-infiltrating-lymphocyte contamination of the IM signature^[10]B.
• Burstein 2015: four subtypes (BLIA, BLIS, MES, LAR) derived from independent integration of gene-expression and DNA methylation data^[11]B.

Multi-omic integrative analyses have reconciled and extended both frameworks, identifying recurring axes of heterogeneity (basal vs mesenchymal, immune-active vs immune-suppressed, androgen-receptor-driven) but without producing a single canonical classifier in clinical use^[12]B. Subtype assignment is not yet routine in clinical practice; it is an active investigational tool, with the LAR subtype the closest to actionable (see androgen-receptor antagonist trials).

Single-cell heterogeneity

Within individual tumors, single-cell RNA sequencing has revealed substantial subclonal diversity, including stem-like and treatment-resistant subpopulations that may seed late recurrence and metastasis^[13]C. Implications for therapy targeting are an active investigational area.

Clinical characteristics

TNBC displays a distinct clinical profile relative to hormone-receptor-positive or HER2-positive disease:

• Higher histologic grade and proliferative index. Most TNBCs are grade 3 with high Ki-67^[14]A.
• Greater early recurrence risk. Recurrence risk is concentrated in years 1–5 after diagnosis, with the hazard then declining below that of hormone-receptor-positive disease, where late recurrence (years 5–20+) remains substantial^[15]A.
• Greater chemosensitivity. Pathologic complete response (pCR) rates after standard neoadjuvant chemotherapy in TNBC are higher than in HR+ disease (historically ~30–40% pre-immunotherapy era) but with worse prognosis among those with residual disease^[16]A.
• Distinct metastatic pattern. Higher rates of visceral metastasis (lung, liver) and central nervous system involvement; the Dana-Farber series reported a 46% lifetime incidence of CNS metastasis in metastatic TNBC^[17]B.

pCR and residual cancer burden (RCB) are strongly prognostic and have been validated as endpoints with regulatory significance^[18]A.

Standard of care

Care has shifted substantially since 2018 with the addition of immune checkpoint inhibitors, antibody-drug conjugates, and PARP inhibitors to the standard regimens. The current landscape, by setting:

Early-stage (stage II–III, and selected high-risk stage I)

• Neoadjuvant pembrolizumab + carboplatin/paclitaxel → pembrolizumab + AC/EC (the KEYNOTE-522 regimen) is the current US/EU standard. Initial publication reported pCR rate 64.8% vs 51.2% with chemotherapy alone^[19]A. The 4-year EFS update confirmed durable benefit (HR ~0.63)^[20]A.
• Adjuvant pembrolizumab continuation for the full 9-month course regardless of pCR status (per the trial protocol).
• Adjuvant capecitabine for residual disease after standard neoadjuvant chemotherapy (CREATE-X precedent^[21]A); applicability after pembrolizumab + chemo regimen is debated but commonly offered.
• Adjuvant olaparib for 1 year in patients with germline BRCA1/2 mutations and high-risk residual disease, based on OlympiA^[22]A.
• Standard surgery and radiation per breast-cancer-general principles; modern hypofractionated regimens are equivalent to extended-fraction schedules for most patients.

Metastatic, first-line

• If PD-L1 CPS ≥ 10: pembrolizumab + chemotherapy (paclitaxel, nab-paclitaxel, or gemcitabine/carboplatin) per KEYNOTE-355. Median OS in the CPS ≥ 10 subgroup ~23 months vs ~16 months with chemo alone^[23]A.
• If germline BRCA1/2: single-agent PARP inhibitor (olaparib per OlympiAD^[24]A or talazoparib per EMBRACA^[25]A) is an option, sequencing relative to chemo individualized to disease pace.
• Otherwise: single-agent chemotherapy (taxane, gemcitabine, carboplatin, capecitabine) chosen for tolerability.

Metastatic, later lines

• Sacituzumab govitecan (anti-Trop-2 ADC with SN-38 payload) after ≥ 2 prior lines, established by ASCENT. Median OS 11.8 vs 6.9 months vs single-agent chemo^[26]A.
• Trastuzumab deruxtecan in HER2-low (IHC 1+ or 2+ with negative ISH) after ≥ 1 prior chemo, established by DESTINY-Breast04 (HR-negative subgroup median OS 18.2 vs 8.3 months)^[27]A.
• PARP inhibitors in BRCA-mutated patients who have not yet received them.
• Single-agent chemotherapy sequenced by tolerability and prior exposure.

Evidence table — pivotal trials

Diagnostic and biomarker considerations

• Germline genetic testing is recommended for all TNBC patients regardless of age or family history, per current NCCN and major society guidelines, given the ~10–20% prevalence of pathogenic BRCA1/2 variants in unselected TNBC cohorts and the direct treatment implications^[7]A.
• PD-L1 testing in metastatic disease uses the Combined Positive Score (CPS) assay (22C3) with CPS ≥ 10 as the eligibility threshold for first-line pembrolizumab. Assay heterogeneity between CPS (22C3) and IC (SP142) scoring complicates cross-trial interpretation^[29]B.
• HER2-low status (IHC 1+ or 2+/ISH-) is now actionable in the metastatic setting; modified IHC reading practices and harmonization between pathologists remain an active concern^[3].
• Tumor-infiltrating lymphocyte (TIL) scoring per the International TILs Working Group standard is prognostic in early-stage TNBC and predicts neoadjuvant pCR; not yet driving treatment selection in routine practice but is broadly recommended for reporting^[30]A.
• HRD scoring beyond germline BRCA1/2 identifies a broader homologous-recombination-deficient population potentially responsive to PARP inhibitors; clinical actionability beyond germline BRCA remains under active investigation^[31]B.

Open questions and active investigation areas

• De-escalation after pCR. Whether the full pembrolizumab adjuvant course is needed in patients who achieve pCR after the neoadjuvant portion is being actively tested; risk of toxicity has to be weighed against possible additional benefit.
• Escalation for residual disease post-KEYNOTE-522. The CREATE-X precedent supports capecitabine for residual TNBC after standard chemo, but the evidence in the immunotherapy era is still maturing. Adjuvant ADCs and biomarker-stratified adjuvant strategies are in trial.
• Sequencing of metastatic therapy. Optimal sequencing of immunotherapy, PARP inhibitors, sacituzumab govitecan, and trastuzumab deruxtecan is not established by head-to-head data; current practice is guided by biomarker positivity and prior-line history.
• HER2-ultra-low and HER2-zero. Whether trastuzumab deruxtecan benefit extends below the current HER2-low threshold is under investigation in DESTINY-Breast06 and follow-on studies.
• Subtype-stratified therapy. LAR subtype response to androgen-receptor antagonists, immune-active (BLIA/IM) subtype enrichment for IO benefit, and mesenchymal-subtype-specific strategies are all being tested but not yet driving routine treatment selection.
• CNS metastasis prevention and treatment. CNS-penetrant ADCs and combinations with intracranial-active small molecules are an under-served and active area.
• Disparities-aware care. Persistent outcome gaps for African American and other under-represented populations are not fully explained by access or biology alone; equity-focused trial design and recruitment are an active area.

References

Each citation links to the original publication via DOI. The same records are searchable in the evidence library by title or DOI.

1. Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. J Clin Oncol. 2020;38(12):1346–1366. doi:10.1200/JCO.19.02309. ↩
2. Wolff AC, Hammond MEH, Allison KH, et al. HER2 Testing in Breast Cancer: ASCO/CAP Clinical Practice Guideline Focused Update. J Clin Oncol. 2018;36(20):2105–2122. doi:10.1200/JCO.2018.77.8738. ↩
3. Tarantino P, Hamilton E, Tolaney SM, et al. HER2-Low Breast Cancer: Pathological and Clinical Landscape. J Clin Oncol. 2020;38(17):1951–1962. doi:10.1200/JCO.19.02488. ↩
4. Howard FM, Olopade OI. Epidemiology of Triple-Negative Breast Cancer: A Review. Cancer J. 2021;27(1):8–16. doi:10.1097/PPO.0000000000000500. ↩
5. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492–2502. doi:10.1001/jama.295.21.2492. ↩
6. Stark A, Kleer CG, Martin I, et al. African ancestry and higher prevalence of triple-negative breast cancer: findings from an international study. Cancer. 2010;116(21):4926–4932. doi:10.1002/cncr.25276. ↩
7. Foulkes WD, Smith IE, Reis-Filho JS. Triple-Negative Breast Cancer. N Engl J Med. 2010;363(20):1938–1948. doi:10.1056/NEJMra1001389. ↩
8. Parker JS, Mullins M, Cheang MCU, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes (PAM50). J Clin Oncol. 2009;27(8):1160–1167. doi:10.1200/JCO.2008.18.1370. ↩
9. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–2767. doi:10.1172/JCI45014. ↩
10. Lehmann BD, Jovanovic B, Chen X, et al. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLoS ONE. 2016;11(6):e0157368. doi:10.1371/journal.pone.0157368. ↩
11. Burstein MD, Tsimelzon A, Poage GM, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015;21(7):1688–1698. doi:10.1158/1078-0432.CCR-14-0432. ↩
12. Bareche Y, Venet D, Ignatiadis M, et al. Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multi-omic analysis. Ann Oncol. 2018;29(4):895–902. doi:10.1093/annonc/mdy024. ↩
13. Karaayvaz M, Cristea S, Gillespie SM, et al. Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-sequencing. Nat Commun. 2018;9(1):3588. doi:10.1038/s41467-018-06052-0. ↩
14. Bianchini G, De Angelis C, Licata L, Gianni L. Triple-negative breast cancer: an evolving moving target. Nat Rev Clin Oncol. 2022;19(2):91–113. doi:10.1038/s41571-021-00565-2. ↩
15. Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13(11):674–690. doi:10.1038/nrclinonc.2016.66. ↩
16. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–172. doi:10.1016/S0140-6736(13)62422-8. ↩
17. Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer. Cancer. 2008;113(10):2638–2645. doi:10.1002/cncr.23930. ↩
18. Symmans WF, Wei C, Gould R, et al. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. J Clin Oncol. 2017;35(10):1049–1060. doi:10.1200/JCO.2015.63.1010. ↩
19. Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020;382(9):810–821. doi:10.1056/NEJMoa1910549. ↩
20. Schmid P, Cortes J, Dent R, et al. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N Engl J Med. 2022;386(6):556–567. doi:10.1056/NEJMoa2112651. ↩
21. Masuda N, Lee SJ, Ohtani S, et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy (CREATE-X). N Engl J Med. 2017;376(22):2147–2159. doi:10.1056/NEJMoa1612645. ↩
22. Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer (OlympiA). N Engl J Med. 2021;384(25):2394–2405. doi:10.1056/NEJMoa2105215. ↩
23. Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy for previously untreated metastatic triple-negative breast cancer (KEYNOTE-355). Lancet. 2020;396(10265):1817–1828. doi:10.1016/S0140-6736(20)32531-9. ↩
24. Robson M, Im SA, Senkus E, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation (OlympiAD). N Engl J Med. 2017;377(6):523–533. doi:10.1056/NEJMoa1706450. ↩
25. Litton JK, Rugo HS, Ettl J, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation (EMBRACA). N Engl J Med. 2018;379(8):753–763. doi:10.1056/NEJMoa1802905. ↩
26. Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer (ASCENT). N Engl J Med. 2021;384(16):1529–1541. doi:10.1056/NEJMoa2028485. ↩
27. Modi S, Jacot W, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer (DESTINY-Breast04). N Engl J Med. 2022;387(1):9–20. doi:10.1056/NEJMoa2203690. ↩
28. Schmid P, Adams S, Rugo HS, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer (IMpassion130). N Engl J Med. 2018;379(22):2108–2121. doi:10.1056/NEJMoa1809615. Atezolizumab approval for metastatic TNBC was subsequently withdrawn in the US in 2021.
29. Adams S, Schmid P, Rugo HS, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of KEYNOTE-086. Ann Oncol. 2019;30(3):397–404. doi:10.1093/annonc/mdy517. ↩
30. Loi S, Drubay D, Adams S, et al. Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. J Clin Oncol. 2019;37(7):559–569. doi:10.1200/JCO.18.01010. ↩
31. Telli ML, Timms KM, Reid J, et al. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. Clin Cancer Res. 2016;22(15):3764–3773. doi:10.1158/1078-0432.CCR-15-2477. ↩

Last reviewed: 2026-05-18. Synthesis pages are re-reviewed when a pivotal trial reads out, when a cited paper is retracted, or annually whichever is sooner. Versioned permalink history is preserved; changes are recorded in the errata and changelog.